More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Paradigm4 has signed an agreement with 54Gene allowing the latter to use the former’s Reveal Biobank App to explore, characterise and query 54Gene’s African Health Information Ecosystem, which is a curated data source of clinical phenotype and genetic information from which insights can be generated to assist the development of
Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis